Company
Nobivac Ducat Data Sheet
Suspension for injection after reconstitution.Presentation
Live, attenuated freeze-dried virus vaccine containing feline viral rhinotracheitis virus, strain G2620A at least 4.8 log10 TCID50*, and feline calicivirus, strain F9 at least 4.6 log10 PFU**. Each vaccine vial contains a single dose for reconstitution in Nobivac Solvent (Vm 01708/4368, VPA 10996/177/1) or Nobivac Rabies (Vm 01708/4325; VPA 10996/170/1) prior to use.
Uses
Active immunisation of cats against feline viral rhinotracheitis (feline herpes virus type I) and feline calicivirus infections. Vaccination reduces clinical signs caused by these viral infections.
Onset of immunity: 4 weeks.
Dosage and administration
One ml Nobivac Solvent or Nobivac Rabies must be used aseptically to reconstitute the lyophilised Nobivac Ducat vaccine immediately prior to use.
One ml of the reconstituted vaccine should be given by subcutaneous injection.
Basic vaccination:
Cats from 8 weeks of age onwards should receive two vaccinations with an interval of 3-4 weeks.
Revaccination:
Annual booster.
In the initial vaccination course, Nobivac Rabies may be used to reconstitute Nobivac Ducat at the vaccination at 12 weeks of age (where this product and the combined use is authorised).
Vaccination at six weeks of age has been proven to be safe.
Contra-indications, warnings, etc.
A slight transient, sometimes painful, swelling (< 5mm) may be observed at the site of injection for one day. A slight temporary rise in rectal temperature may occur, while occasionally transient lethargy may be observed during the first day after vaccination.
In rare cases the vaccine may cause hypersensitivity reactions (pruritis, dyspnoea, vomiting, diarrhoea and collapse).
Care should be taken that an aerosol is not formed when vaccinating the cat as nasal or oral exposure could result in clinical respiratory signs including lethargy and malaise. For the same reason, the cat should be prevented from licking the injection site.
Do not use during pregnancy and lactation as the product has not been tested in pregnant and lactating queens.
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other, except Nobivac Rabies, where this product and the combined use is authorised.
It is therefore recommended that no other vaccines should be administered within 14 days before or after vaccination with Nobivac Ducat.
An overdose can lead to a transient swelling (<5 mm) at the injection site which may persist for four to ten days. A transient increase in temperature (<40.8°C) may occur while occasionally lethargy for one day after vaccination may be observed.
________________________
* tissue culture infectious dose
** plaque forming units
Operator warning:
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Withdrawal period:
Not applicable.
FOR ANIMAL TREATMENT ONLY. KEEP OUT OF REACH AND SIGHT OF CHILDREN.
Pharmaceutical precautions
Vaccine: Store in original package between +2°C and +8°C. Do not freeze.
Keep protected from light. Keep the container in the outer carton.
Nobivac Solvent: Can be kept between +15°C and +25°C if stored independently from the vaccine.
Disposal advice:
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.
Legal category
POM-V To be supplied only on veterinary prescription.
Package quantities
Nobivac Ducat may be presented in cartons containing 10 or 50 single dose vials. Solvent may be packed together with the vaccine or separately.
Further information
Avoid contamination of the vaccine with traces of sterilising agents. Do not use chemicals such as disinfectants or spirit to disinfect the skin prior to inoculation.
Only healthy cats should be vaccinated.
The vaccine may not be effective in cats incubating the disease at the time of vaccination.
Cats that received the corresponding antiserum or immunosuppressive drugs should not be vaccinated until an interval of at least 4 weeks has elapsed.
In the event of an allergic reaction immediate treatment should be given with an antihistaminic, corticosteroid or adrenaline by the suitable route of administration.
Marketing Authorisation number
Vm 06376/4040 UK authorised veterinary medicinal product.
Marketing Authorisation holder
Intervet International BV
represented by:
Intervet UK Ltd.
Walton Manor
Walton
Milton Keynes
MK7 7AJ
Date of text preparation
17/05/06